Abstract Serum h 2 -microglobulin, the light chain of the HLA class I molecular complex, remains one of the best survival prognostic factors in multiple myeloma, but other HLA class I molecules might be of interest in monoclonal gammopathies. In this study, we evaluate total soluble HLA class I (HLA-Is) and soluble HLA-G (HLA-Gs) in103 patients with newly diagnosed multiple myeloma, 30 patients with monoclonal gammopathy of undetermined significance (MGUS), and 30 healthy subjects, studying their prognostic value in multiple myeloma. In multiple myeloma patients, HLA-Is and HLA-Gs medianvalues were 0.8 Ag/mL and 28 ng/mL, respectively. Median HLA-Is concentration was higher in stage IIand IIImultiple myeloma patients than in stage Imultiple myeloma, MGUS, and control patients. Median HLA-Gs was significantly lower in healthy controls than in MGUS and multiple myeloma patients. A high level of HLA-Is (z2
In multiple myeloma, h 2 -microglobulin is widely recognized as one of the most useful survival prognostic factors (1) . Among several staging systems using h 2 -microglobulin, the h 2 -microglobulin and albumin combination is of particular interest (2) and has been recently validated in the context of the International Staging System (3). Other staging systems using more sophisticated variables such as cytogenetics could also emerge in the future (4) .
The serum h 2 -microglobulin is the light chain of the HLA class I molecular complex, expressed on the surface of the majority of nucleated cells (5) , and corresponds to the serologic soluble HLA heavy chain -free h 2 -microglobulin (6) . Because serum h 2 -microglobulin is an important feature in multiple myeloma, other HLA class I molecules may be of interest in monoclonal gammopathies. Soluble HLA class I molecules (HLA-Is) as well as the main soluble HLA-G isoform (HLA-Gs) are known to have immunosuppressive properties (7) . This immunomodulating role is partially explained by their capacity to protect target cells from natural killer and T cytolysis and to trigger apoptosis in activated T CD8 + cells (8, 9) . The cell origin and pathway of HLA-Is secretion in multiple myeloma remain unclear. Several soluble h 2 -microglobulin -associated HLA class I heavy chains are generated by different mechanisms: the full-length lipid-associated protein (44000 Da) generated by exosomal shedding, the truncated protein (39000 Da) resulting from alternative splicing, and the proteolytic form (35000 Da) released by metalloproteinasemediated cleavage (10) . However, as several metalloproteinases are produced by human myeloma cells and seem to play a critical role in the pathogenesis of multiple myeloma (11, 12) , this suggests a critical proteolytic pathway involvement.
A recent study suggested that the soluble h 2 -microglobulinfree HLA class I heavy chain expression could be a disease marker in multiple myeloma (13) . In a tumoral process, HLA-G expression could constitute a mechanism of tumor progression, and HLA-Gs expression has been shown in various cancer types and in some lymphoproliferative disorders (14 -17) .
In this study, we evaluate the levels of soluble associated h 2 -microglobulin/HLA-G5 (HLA-Gs) and total HLA-Is in patients with multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), and in age-matched healthy subjects. We also studied their potential prognostic value on survival in multiple myeloma, especially in relation to h 2 -microglobulin.
Patients and Methods
Patient selection. One hundred and three patients with multiple myeloma diagnosed between 1989 and 2000 in the center of Lille according the criteria of the International Myeloma Working Group (18) and staged according to the Durie/Salmon staging system (19) were included in the study. The patient characteristics are given in Table 1 . The patients were always treated after serum collection according to the Intergroupe Francais du Myelome protocols, receiving either conventional chemotherapy (n = 53) or high-dose therapy with autologous peripheral blood stem cell support (n = 38). Twelve patients remained untreated at the date of point. For treated patients, the median time between serum collection and treatment was 0.3 month (interquartile range, 0.0-2.9).
Thirty patients with MGUS diagnosed according to the International Myeloma Working Group (ref. 18 ; 17 females and 13 males) and 30 age-matched healthy subjects were also studied. MGUS patients had a median age of 62 years (interquartile range, 56-68) and their median bone marrow plasmacytosis was 3% (interquartile range, 2-5). At the date of point, no patient had progressed to multiple myeloma.
Laboratory variables. The biological evaluations were done in Lille for usual variables and Rennes for soluble HLA class molecules. Chromosome 13 deletion (D13) was determined using fluorescence in situ hybridization analysis (20) . HLA-Gs and HLA-Is concentrations were measured using a specific sandwich ELISA. Microtiter plates (Corning Costar, Brumath, France) were coated in PBS at pH 7.4 with MEM-G/9 (10 Ag/mL), a monoclonal antibody detecting specifically HLA-Gs molecules associated with h 2 -microglobulin (Exbio, Prague, Czech Republic) or with W6/32 (5 Ag/mL), monoclonal antibody recognizing a monomorphic determinant of h 2 -microglobulin associated to any of the HLA class I heavy chains (Harlan Sera-Lab Ltd., Leicestershire, England). After three washes in PBS containing 0.05% Tween 20, plates were saturated with 250 AL of PBS containing 2% bovine serum albumin for 30 minutes at room temperature. One hundred microliters of pure sera for HLA-Gs or diluted at 1/50 in PBS for HLA-Is were added to each well and tested in triplicate. After incubation for 1 hour at room temperature, plates were washed thrice in PBS with 0.05% Tween 20. Anti-h 2 -microglobulin/horseradish peroxidase (DAKO, Trappes, France; 100 AL) was added to each well and plates were incubated for 1 hour at room temperature. Plates were washed thrice and then incubated with the substrate (orthophenylenediamine dihydrochloride, DAKO) for 30 minutes in dark. After addition of H 2 SO 4 (1 N), absorbencies were measured at 490 nm. Standard curves were done using serial dilutions of either calibrated supernatant of B-lymphoblastoid cell line LCL-721.221 (American Type Culture Collection, Rockville, MD) transfected with HLA-Gs cDNA (LCL721.221-G5), kindly provided by V. Rebmann (Essen, Germany). Soluble HLA-B7s molecules (Sangstat, Fremont, CA) were used as a standard to calculate the total amount of sHLA-I antigens. Thus, the concentrations of HLA-Gs and HLA-Is were determined from the value of absorbance according to the standard curves.
Statistical analysis. The distributions of HLA-Is and HLA-Gs levels among the different groups (controls, MGUS, and multiple myeloma by stage) were characterized through median and interquartile range. 
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Abbreviations: LDH, low-density hydrocarbon; CRP, C-reactive protein. time from serum collection and after first conventional or intensive treatment, respectively (21) . In addition to HLA-Is and HLA-Gs, all variables described in Table 1 were examined for their prognostic value on overall survival. In these prognostic analyses, continuous variables were categorized based on 25th, 50th, and 75th percentiles, as described previously (22) . Usual limits (as 2.5, 4.0, and 6.0 mg/L for h 2 -microglobulin) were also tested. For univariate analyses, overall survival curves were compared through log-rank test (23) . The estimate of the relative risk of death and its 95% confidence interval was estimated through proportional hazards model (24) . Then, the ability of each variable, HLA-Is and HLA-Gs, to increase overall survival predictive ability of the h 2 -microglobulin was tested through backward stepwise proportional hazards model using likelihood ratio test (25) . The subsequent prognostic models were simplified by using the same procedure, as the one described for univariate analysis of continuous prognostic variable, leading to final models with three or four categories only. No further improvement by adding another factor in the model was looked for according to the sample size and the number of deaths in our sample. The influence of patient treatment on these prognostic models was investigated by testing their prognostic ability through a proportional hazards model including conventional and intensive treatments as time-dependent covariates (26) .
The respective qualities of our final models and of some well-known previously published models (2, 3, 22, 27, 28) applied to our sample were described through Kaplan-Meier estimates of survival curves and quantified through the value in À2log (likelihood), the lower value corresponding to the best fit of data for a fixed number of prognostic categories and the same sample size. All analyses were done with the SPSS software (29) .
Results
HLA-Is and HLA-Gs serum levels and correlations to other variables. As described in Table 2A , HLA-Is concentration varied across stages in multiple myeloma patients (P = 0.02) but not between stages II and III (P = 0.88). A statistically significant difference was observed between stage I and stage II to III multiple myeloma (P = 0.005), with higher values for the latter group. In contrast, no significant differences were observed between controls and MGUS and between MGUS and stage I multiple myeloma. Regarding HLA-Gs (Table 2B) , there was no variation across stages in multiple myeloma patients and between MGUS and multiple myeloma patients. The only difference was evidenced between controls and MGUS (P = 0.03) or multiple myeloma (P < 0.001). No variation of HLA-Is and HLA-Gs with age could be evidenced among multiple myeloma patients. No correlation was observed between HLA-Is and HLA-Gs. HLA-Is showed a minor correlation with h 2 -microglobulin in stage I (r = 0.44, P = 0.005), stage II to III multiple myeloma (r = 0.27, P = 0.03), and in the entire multiple myeloma population (r = 0.29, P = 0.003). In contrast, HLA-Gs did not correlate with h 2 -microglobulin in multiple myeloma regardless of disease stage. Minor correlations of HLA-Is with hemoglobin (r = À0.23, P = 0.02) or bone marrow plasmacytosis (r = 0.23, P = 0.02) were observed but only globally in multiple myeloma patients, as a consequence of their variations across stages. Both HLA markers did not correlate to creatinine and to chromosome 13 deletion.
Survival analyses.
In multiple myeloma, the median follow-up time was 73.2 F 5.4 months and the median survival time was 51.4 F 5.8 months (65 deaths). Among the 91 treated multiple myeloma patients, 64 progressions were observed and the median progression-free survival time was 18.8 F 1.7 months. Variables significantly affecting overall survival in univariate analysis are presented in Table 3 . A high level of HLA-Is (z2.1 Ag/mL) was predictive of a short overall survival, as shown on Fig. 1 . In contrast, HLA-Gs level had no effect on overall survival. There was a trend in patients with increasing h 2 -microglobulin level but not in those with high HLA-Is level to shorter progression-free survival (P = 0.08 and P = 0.55, respectively). In the multivariate analysis, h 2 -microglobulin (P < 0.001) and HLA-Is (P = 0.047) were independent prognostic factors affecting overall survival. Relative risk of death (95% confidence interval) was 2.1 (1.2-3.7) for patients with h 2 -microglobulin between 2.5 and 4.0 mg/L and 3.6 (1.9-6.9) for patients with h 2 -microglobulin z 4.0 mg/L compared with patients with h 2 -microglobulin < 2.5 mg/L and 1.8 (1.0-3.2) for patients with HLA-Is z 2.1 Ag/mL compared with patients with HLA-Is < 2.1 Ag/mL. Based on these results, a prognostic model with four categories was derived (Table 4 ; Fig. 2A ): 1 point was given for a h 2 -microglobulin level between 2.5 and 4.0 mg/L; 2 points if h 2 -microglobulin level was z4.0 mg/L; and 1 point if HLA-Is level was z2.1 Ag/mL, the risk of death increasing with the score or total of points. This classification seemed clearly different from the one obtained with h 2 -microglobulin alone (Table 3 ; Fig. 2B ).
The h 2 -microglobulin/HLA-Is model still strongly affected overall survival when taking into account conventional and intensive treatments as time-dependent covariates (P = 0.009). This prognostic classification, as well as the one based on h 2 -microglobulin alone, had only a borderline significance on progression-free survival (P = 0.15 and 0.08, respectively).
Comparison between prognostic models. We did the comparison of the h 2 -microglobulin/HLA-Is model with some previously published models. Our previous model using h 2 -microglobulin, fluorescence in situ hybridization D13, and IgA isotype (22) was superior to the h 2 -microglobulin/HLA-Is model, the latter was superior to the Southwest Oncology Group h 2 -microglobulin/albumin model (28), À2log (likelihood) being estimated to be 279.700, 286.813, and 292.362, respectively. To compare our model with previous models (Table 4) . In these conditions, the combination of h 2 -microglobulin and D13 was the most effective model followed by the combination of h 2 -microglobulin and HLA-Is with À2log (likelihood) estimated on 70 patients to be 294.023 and 296.721, respectively. The combination of h 2 -microglobulin and Creactive protein (27) provided inferior models (data not shown). The h 2 -microglobulin and albumin model which constitutes the basis of the simplified International Staging System (3) was also inferior in this series of patients, À2log (likelihood) being estimated on 103 patients to be 516.638 compared with 507.451 for the h 2 -microglobulin/HLA-Is model.
Discussion
This study suggests that HLA-Is is a new marker of multiple myeloma tumor load, with higher levels found in Durie Salmon stage II/III multiple myeloma compared with stage I multiple myeloma, MGUS, and healthy controls. HLA-Gs was higher in all kinds of monoclonal gammopathies compared with controls. Correlations between these markers and usual multiple myeloma variables were poor, except between HLA-Is and h 2 -microglobulin. In multiple myeloma, a high level of HLA-Is but not of HLA-Gs was associated with a poor survival. The combination of h 2 -microglobulin and HLA-Is provided a powerful prognostic model, a high level of HLA-Is identifying patients with a more severe prognosis, compared with a low level, for any level of serum h 2 -microglobulin. This prognostic model seemed more efficient than other previously published models, except the combination of h 2 -microglobulin and chromosome 13 deletion (22) .
To our knowledge, the main soluble HLA-G isoform, a nonclassic MHC class I molecule, have not been studied in multiple myeloma, but it has been investigated in other lymphoproliferative disorders: chronic lymphocytic leukemia and B and T non-Hodgkin lymphoma (14 -17) . In all these cases, the HLA-G molecules were at low density on the tumoral cell surface contrasting with the frequent detection of the soluble isoform. Approximately 60% of B-and T-lymphoid malignancies have significantly increased HLA-Gs levels compared with healthy subjects with mean levels equal to 49 and 47 ng/mL in chronic lymphocytic leukemia and B nonHodgkin lymphoma, respectively (17) . A study reported an increased level of HLA-G expression at the cell surface of T-and B-primary cutaneous lymphoma, but they did not consider the soluble isoform (30) . These differences between cutaneous lymphoma and their nodal or leukemic counterparts could be partially explained by differences regarding the microenvironment and especially the cytokines involved (17) . The serologic h 2 -microglobulin-free HLA class I heavy chain (FHC) has been recently studied (13) . The total soluble HLA class I complex, a couple of h 2 -microglobulin and the HLA class I heavy chain, seems more stable than the h 2 -microglobulinfree HLA class I heavy chain (31) . FHC levels were significantly higher in multiple myeloma compared with MGUS and controls but did not vary across multiple myeloma stages (13) . Similar minor correlations were observed between HLA-Is or FHC and h 2 -microglobulin (r = 0.29 or 0.31, respectively) and bone marrow plasmacytosis (r = 0.29 and 0.36, respectively). HLA molecules levels, total soluble or FHC, were not correlated to creatinine (r = 0.09 and 0.15, respectively). This result was expected as the HLA-I heavy chain is heavier than the h 2 -microglobulin molecule and is more susceptible to catabolism rather than renal filtration. The importance of finding a new marker independent of creatinine in multiple myeloma has been stressed because h 2 -microglobulin is influenced by renal insufficiency and is normal in about 10% of patients (6, 32) . No real prognostic factor analysis was done in the study reported by Perosa et al. (13) . In our study, the 2.1 Ag/L threshold, the upper limit of the inter-quartile range, was derived from overall survival prognostic analysis. We did not do a systematic research of the most effective limit as provided by ROC curve analysis, because it is known to provide limit highly dependent on the studied sample. For every h 2 -microglobulin level, <2.5 mg/L, between 2.5 and 4 mg/L, and z4.0 mg/L, an HLA-Is level of z2.1 Ag/L reclassified patients in a worse prognostic group, concerning one third of patients within each level of h 2 -microglobulin.
The HLA-Is/h 2 -microglobulin model was shown to be more effective than previously proposed models, except the D13/h 2 -microglobulin model (22) . Of note, all the models including h 2 -microglobulin and albumin (2, 3, 28) seemed much less effective than the h 2 -microglobulin/HLA-Is model. This needs to be confirmed in other studies because the comparison between these models was done on a sample that was optimal for the HLA-Is/h 2 -microglobulin model, because it was used to construct this model. Furthermore, it should be valuable to test on a sufficiently large sample the prognostic ability of the combination HLA-Is/D13/h 2 -microglobulin. Anyway, the HLAIs/h 2 -microglobulin model seemed an effective alternative to the D13/h 2 -microglobulin model for investigators lacking cytogenetics.
HLA-Gs was of no survival prognostic value in multiple myeloma, contrarily to HLA-Is. The reason for the discrepancy observed by others that described a prognostic role of HLA-Gs in other B-lymphoid malignancies (14 -17) underlined the particularity of the multiple myeloma pathogenesis. The reasons why HLA-Is seemed of prognostic value in multiple myeloma remain unclear. Its prognostic role could be related to its biological activities, especially its immunosuppressive properties. On the other hand, our HLA-Is ELISA evaluation, measuring a couple of h 2 -microglobulin and the HLA class I heavy chain, could be a way to measure the complementary part of h 2 -microglobulin not quantified by the dosage of h 2 -microglobulin alone (free h 2 -microglobulin).
In conclusion, in our study, HLA-Gs had no survival prognostic effect in multiple myeloma but was a marker of clonality. In contrast, HLA-Is gave strong additional survival prognostic information to h 2 -microglobulin alone, leading to a powerful prognostic score. This new prognostic classification needed to be confirmed in other patient cohorts.
